Yasin Emrah Soylu

Dr. Yasin Emrah Soylu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ATAykut Turhan
Aykut Turhan
MBMehmet Emin Buyukbayram
Mehmet Emin Buyukbayram
ZHZekeriya Hannarici
Zekeriya Hannarici
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
YSYasin Emrah Soylu
Yasin Emrah Soylu
STSalim Başol Tekin
Salim Başol Tekin
Background: Gastric cancer remains a leading cause of cancer mortality, and additional prognostic tools reflecting host inflammation and nutritional status are needed, particularly in patients receiving neoadjuvant regimens such as fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT). This study aimed to evaluate the prognostic significance of the Gustave Roussy Immune (GRIm) score in patients with locally advanced gastric cancer treated with neoadjuvant FLOT. Methods: This retrospective single-center study included 128 patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with neoadjuvant FLOT between 2018 and 2022. The GRIm score, based on albumin, lactate dehydrogenase (LDH), and neutrophil-to-lymphocyte ratio (NLR), was used to stratify patients into low- and high-risk groups. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier and Cox proportional hazards regression models. Results: Among 128 patients (mean age, 61.5 years; 63.3% male), 69.5% underwent surgical resection, and 24.7% achieved a pathological complete response. During a median follow-up of 36.9 months, 57.0% of patients experienced disease progression and 48.4% died. The median OS and PFS were 49.9 and 25.5 months, respectively. The GRIm score demonstrated moderate discriminative ability for mortality (area under the curve [AUC]: 0.704) and was significantly associated with survival. The median OS was shorter in the high-risk group than in the low-risk group (35.2 vs. 69.6 months, p < 0.001), and the median PFS was also shorter in the high-risk group (17.2 months vs. not reached, p < 0.001). In the multivariate analysis, high GRIm risk remained independently associated with worse OS (hazard ratio [HR]: 1.832, p = 0.030) and PFS (HR: 2.491, p < 0.001), along with age, clinical stage, and surgical resection status. Conclusions: In this single-center retrospective cohort study, the GRIm score was associated with survival outcomes in patients with locally advanced gastric or GEJ adenocarcinoma receiving neoadjuvant FLOT. These findings suggest that the GRIm score may provide additional risk stratification when interpreted in conjunction with established clinical factors. However, external validation in larger prospective cohorts is required before it can be applied in routine clinical practice.

18 March 2026 in BMC Cancer
Verified
Journal Article
Open access
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
ZHZekeriya Hannarici
Zekeriya Hannarici
MBMehmet Emin Buyukbayram
Mehmet Emin Buyukbayram
ATAykut Turhan
Aykut Turhan
YSYasin Emrah Soylu
Yasin Emrah Soylu
STSalim Başol Tekin
Salim Başol Tekin
Lung cancer is the most prevalent malignancy worldwide and the leading cause of cancer-related deaths. The adrenal gland is a frequent site of metastasis in non-small cell lung cancer (NSCLC). The differentiation of adrenal metastases from benign lesions is imperative for accurate staging and treatment planning. Imaging methods such as FDG-PET/CT, CT, and MRI provide important diagnostic information; however, false negative and false positive results may occur with these methods. The employment of clinical, biochemical, and radiological predictors has the potential to enhance diagnostic precision. A retrospective cross-sectional study was performed on NSCLC patients diagnosed between 2015 and 2025. From 2,194 lung cancer cases, 121 patients who exhibited adrenal lesions on initial PET/CT and had no extrathoracic metastases were included. Clinical data (age, sex, T-N stage), biochemical markers (CEA, CA125) and radiological parameters (SUVmax, lesion size, laterality) were obtained. The relationship of these parameters with the presence of adrenal metastasis was systematically evaluated in order to identify potential predictors. Of 121 patients, 86 had adrenal metastases and 35 had benign adrenal lesions. Malignant lesions demonstrated significantly higher SUVmax, larger size, and elevated CEA and CA125 levels. ROC analysis revealed optimal cut-off values: SUVmax > 3.05 (AUC = 0.86, sensitivity 89%, specificity 69%), CEA > 4.45 ng/mL, CA125 > 24.5 U/mL, and lesion size > 14.5 mm. Multivariate regression identified N3 stage (OR = 12.75, p = 0.043), elevated CEA (OR = 1.02, p = 0.038), and lesion size (OR = 1.09, p = 0.037) as independent predictors of metastasis. Most patients with metastasis were diagnosed at advanced stages, with 91.9% being T3–4 or N2–3. The present study demonstrates that SUVmax, lesion size, CEA, T stage, and N stage are significantly associated with adrenal metastasis in NSCLC. Integrated assessment of these clinical, biochemical, and radiological parameters can improve the differentiation of adrenal metastases from benign lesions, facilitating more accurate staging and treatment planning. The online version contains supplementary material available at 10.1186/s12885-026-15878-7.

15 January 2025 in Medical Records
Verified
Journal Article
Open access
PDF file
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
ATAykut Turhan
Aykut Turhan
PEPınar Çoban eşdur
Pınar Çoban eşdur
YSYasin Emrah Soylu
Yasin Emrah Soylu
MBMehmet Bilici
Mehmet Bilici
STSalim Başol Tekin
Salim Başol Tekin
Aim: Cancer is a major cause of death. Globocan data shows 20 million new cancer cases and 9.7 million cancer deaths a year. Lung cancer is the most common cancer globally, followed by breast, colorectal, prostate and stomach cancers. Cancer types vary by age, gender, race, and region. Documenting regional cancer data is crucial for screening, early diagnosis, and treatment of common cancers, as well as understanding the underlying causes. Despite the high incidence of upper gastrointestinal (GI) cancers in eastern Türkiye, there is little documented evidence on specific cancer types in these regions. Material and Method: In order to investigate the incidence of cancer in our region, the medical records of 6,603 patients diagnosed with cancer and subsequently treated in our clinic between 2018 and 2023 were analysed and specific cancer sites were recorded. Results: It has been demonstrated that cancers of the upper GI tract, represent the most prevalent cancer site, accounting for 21.2% (n=1403) of all cases. This equates to one in every five patients diagnosed with cancer. Additionally, significant findings were yielded with respect to other forms of cancer. Conclusion: It is imperative to document these data to highlight the necessity for investigating and preventing the underlying causes of upper GI cancer in our region. Furthermore, the establishment of screening programs for early diagnosis and intensified research on treatment modalities are crucial steps in combating this disease.

Verified
Journal Article
Open access
PDF file
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
ZHZekeriya Hannarici
Zekeriya Hannarici
MBMehmet Emin Buyukbayram
Mehmet Emin Buyukbayram
ATAykut Turhan
Aykut Turhan
YSYasin Emrah Soylu
Yasin Emrah Soylu
STSalim Başol Tekin
Salim Başol Tekin
Background: Accurate prognostication in terminal cancer patients receiving best supportive care (BSC) is essential for guiding end-of-life decision-making and avoiding non-beneficial interventions. Several prognostic models have been developed for advanced cancer, including the Palliative Prognostic Index (PPI) and the Objective Prognostic Score (OPS). However, prospective data evaluating their performance specifically in patients managed with BSC are limited. This study evaluated the prognostic performance of PPI and OPS in terminal cancer patients receiving BSC. It also examined whether their combined use provides additional value for short-term mortality risk stratification. Methods: This prospective observational cohort study included hospitalized adult patients with terminal-stage cancer and a documented BSC decision. Terminal-stage cancer was operationally defined as stage IV malignancy with poor performance status and no remaining feasible disease-directed oncological treatment option due to severe clinical deterioration and/or major organ dysfunction. Patients were prospectively enrolled from 12 April 2024 to 13 December 2024 and followed until death. Eligible patients had poor Eastern Cooperative Oncology Group performance status (ECOG 3–4) and had not received oncologic treatment within the preceding month. PPI and OPS were calculated at baseline using predefined criteria. Survival time was defined as the interval between baseline assessment and death. The prognostic performance of the scores for 3-, 4-, and 6-week mortality was evaluated, and survival outcomes were analyzed using standard survival analysis methods. Results: A total of 112 patients were included in the final analysis. The mean age was 62.3 ± 12.3 years; 66 patients (58.9%) were male and 46 (41.1%) were female. The most common primary tumor sites were colon cancer (20.5%), non-small cell lung cancer (17.0%), and gastric cancer (15.2%). Both PPI > 6 and OPS ≥ 3 were associated with higher short-term mortality, although their individual discriminatory performance was modest. The combined OPS–PPI approach showed statistically significant but still modest discrimination at all time points. Although this difference was limited, the combined approach supported the stratification of a clinically relevant subgroup at particularly high risk of imminent death. Patients with both OPS ≥ 3 and PPI > 6 had the poorest survival, with a median overall survival (OS) of 11 days. In multivariable Cox regression analysis, the combined high-risk group remained independently associated with poorer OS (HR 1.53, 95% CI 1.01–2.31; p = 0.046). Conclusions: Although the individual discriminatory performance of PPI and OPS was modest, their combined use may provide additional risk stratification value and may help identify patients at particularly high risk of short-term mortality among terminal cancer patients receiving BSC. These findings should be interpreted as supporting bedside risk stratification rather than indicating a definitive individual-level prediction model.